Geron GERN
Geron Q3 FY25: revenue $47.2M, up 67%; diluted EPS −$0.03
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000886744-25-000071
Key figures from this report
These are the numbers Geron reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$47.2M+67% from $28.3M in Q3 FY2410-Q income statement, on EDGAR
- Net income−$18.4MAgainst −$26.4M in Q3 FY2410-Q income statement, on EDGAR
- Diluted EPS−$0.03Against −$0.04 in Q3 FY2410-Q income statement, on EDGAR
- Cash and cash equivalents$78.1M+29% from $60.3M in Q3 FY2410-Q balance sheet, on EDGAR
- Cash from operations−$13.6MAgainst −$58.9M in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
- Wave Life Sciences WVE public float $851M, Jun 30, 2025
- CorMedix CRMD public float $910M, Jun 30, 2025
- Niagen Bioscience NAGE public float $814M, Jun 30, 2025
- Nurix Therapeutics NRIX public float $808M, May 30, 2025
